Taysha Gene Therapies, Inc. (TSHA)

Every figure this model derived for TSHA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 381,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 455,407,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 461,434,000 AssetsCurrent 2026-06-30
current liabilities 25,975,000 LiabilitiesCurrent 2026-06-30
equity 387,266,000 StockholdersEquity 2026-06-30
interest expense 42,000 InterestExpenseNonoperating 2026-06-30
ocf -132,191,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 5,485,000 Revenues 2026-06-30
sbc 18,171,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TSHA on one particular measure came for.

RatioValue
cash operating margin-2439.27
current ratio22.52
current ratio reported17.76
deferred revenue growth-53.5
dilution pct27.84
fcf margin-2416.99
growth cv1.55
interest cover-3646.64
revenue growth-32.27
revenue growth per share-47.02
rule of 40-2824.59
sbc pct revenue331.29

What to be careful about

What this model itself distrusts about TSHA's figures. Written by the derivation as it ran, not added afterwards.